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Summary Intrinsic resistance to existing clinical platinum drugs is a major cause of treatment failure;
moreover, these agents have the drawbacks of cross-resistance and intravenous administration. The mechanism
of intrinsic cisplatin resistance and the mechanism of circumvention of intrinsic resistance by a member
(JM221) of the ammine/amine platinum (IV) dicarboxylate class of platinum complex was studied in
intrinsically resistant (SKOV-3) and sensitive (41M) human ovarian carcinoma cell lines. JM221 reduced the
cisplatin resistance factor nine- to 2.7-fold, was more potent than cisplatin and showed marked time-dependent
cytotoxicity. Cellular platinum accumulation was 20- to 40-fold greater (P <0.001), and DNA platination was
fourfold greater (P<0.02), immediately following 2 h equimolar exposure to JM221, compared with cisplatin.
DNA platinum levels decreased following cisplatin exposure with a half-life approximating 48 h in both lines,
while no net removal of DNA-bound platinum was recorded following JM221 exposure. JM221 caused DNA
interstrand cross-linking, but this was 10-20% less frequent with JM221 than with cisplatin when expressed as
a proportion of total DNA platinum lesions. Cisplatin DNA interstrand cross-linking was twofold greater in
the intrinsically sensitive line (41M) than in the resistant line (SKOV-3) over a range of concentrations and
time-points. Neither cellular platinum accumulation, levels of DNA platination nor the rate of removal of
DNA-bound platinum in the two cell lines related to their ninefold difference in cisplatin sensitivity. Intrinsic
cisplatin resistance appears to be attributable to the inhibition of formation of bifunctional DNA lesions,
while the circumvention of intrinsic resistance by JM221 seems to be the result of both improved transport
properties and circumvention of DNA repair mechanisms.
Cisplatin and carboplatin are the standard agents for the
treatment of advanced ovarian adenocarcinoma. Although
the latter drug causes less non-haematological toxicity
(Alberts et al., 1992), both are cross-resistant in this cancer
(Gore et al., 1989) and are intravenous preparations. A
major focus for drug discovery initiatives has been the
attempted development of antitumour platinum complexes
with activity in cisplatin-refractory disease. In this regard, the
diaminocyclohexane platinum complexes, which circumvent
cisplatin resistance in murine leukaemia models, are promis-
ing. However, their non-cross-resistant properties have not
been confirmed in clinical trials and neurotoxicity is a limita-
tion in humans (Extra et al., 1990; O'Rourke et al., 1993). A
new class of platinum complex, the ammine/amine platinum
(IV) dicarboxylates, appear to have two principal preclinical
advantages over the existing drugs: firstly, their in vitro
activity in cisplatin-resistant human cancer cell lines (Kelland
et al., 1992) and, secondly, their bioavailability and
antitumour activity when administered via the oral route
(Harrap et al., 1991).
Ovarian cancer is the fifth most common cause of cancer
death among British women (HMSO Mortality statistics,
1988, series DBH2, No. 15.) and is advanced at the time of
presentation in the majority of cases (Jacobs & Oram, 1990).
The conventional multimodality approach of debulking
surgery and platinum chemotherapy is associated with
tumour responses of 60% but a low overall long-term sur-
vival (Neijt et al., 1991). The majority of women with
ovarian cancer die of drug-refractory disease that either
failed to respond (intrinsic resistance) or recurred after an
initial response (acquired resistance) to platinum-based
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chemotherapy. The mechanisms of in vitro-acquired cisplatin
resistance have been intensively studied of late (Andrews &
Howell, 1990), but few investigations have focused on the
problem of intrinsic resistance. This paper describes studies
addressing the issues of, firstly, the mechanism of cisplatin
resistance in an intrinsically resistant human ovarian car-
cinoma and, secondly, the mechanism of the circumvention
of intrinsic cisplatin resistance by the ammine/amine
platinum (IV) dicarboxylate class of platinum complex.
The experiments described herein compare the action of
cisplatin with an example of the ammine/amine platinum
(IV) dicarboxylate class (JM221) in an intrinsically sensitive
(41M) and an intrinsically resistant (SKOV-3) human
ovarian carcinoma cell line pair. The 41M line was originally
established from an ascitic sample taken from a woman with
ovarian cancer prior to any chemotherapy, and the SKOV-3
line was established from an ascitic sample from a patient
previously treated with the alkylating agent thiotepa. Neither
cell line had previously been exposed to platinum-based
drugs in vitro or clinically, yet they showed a difference in in
vitro cisplatin sensitivity of approximately tenfold (Hills et
al., 1989). In vitro-acquired cisplatin resistance has often been
attributed to decreased transport, thiol inactivation or en-
hanced DNA repair, or to a combination of these mechan-
isms (Andrews & Howell, 1990). The role these mechanisms
play in intrinsic resistance is unknown, but the SKOV-3 line
is known to contain higher levels of glutathione than the
41M line (Mistry et al., 1991). A previous report described
the non-cross-resistant properties of JM221 in the SKOV-3
cell line, and suggested that this may be attributable to
increased uptake (Kelland et al., 1992). The experiments
herein focus on the DNA interactions of cisplatin and JM221
in the SKOV-3 and 41M cell lines, with further studies on
the transport properties, by the measurement of total cellular
and DNA platinum content, DNA interstrand cross-linking
and cytotoxicity. It was found that the activity of JM221 is
attributable to improved transport and the circumvention of
DNA repair mechanisms, while intrinsic cisplatin resistance is
due to decreased DNA interstrand cross-linking.
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Materials and methods
Chemicals
Cisplatin and JM221 (Figure 1) were synthesised and sup-
plied by the Johnson Matthey Technology Centre, Reading,
Berkshire, UK. Cisplatin was dissolved in 0.9% sodium
chloride (w/v) and JM221 was dissolved in absolute ethanol.
The final ethanol concentration in tissue culture medium was
below growth-inhibitory levels [<0.5% (v/v)]. Chemicals
were otherwise obtained from Sigma, unless stated.
Cell lines
The biological properties of the two human ovarian car-
cinoma cell lines used (SKOV-3 and 41M) have been de-
scribed previously (Hills et al., 1989). Both are ovarian
adenocarcinomas with broadly similar doubling times
(SKOV-3, 19 h; 41M, 27 h), differences in chromosomal con-
tent (SKOV-3, aneuploid; 41M, diploid), contrasting in vitro
sensitivity to platinum complexes, and are CA125 marker
positive. Both were established from ascitic samples, prior to
any cytotoxic therapy in the case of the 41M line and follow-
ing thiotepa treatment for the SKOV-3 line. Neither cell line
had been previously exposed to platinum drugs in vitro. Both
cell lines were grown as monolayer cultures in Dulbecco's
modified Eagle medium plus 10% fetal calf serum, 50yg ml-'
gentamicin, 2.5lLgml-' amphotericin B, 2mM L-glutamine,
10 gml-' insulin and 0.5tLgml-' hydrocortisone in a 10%
carbon dioxide-90% air atmosphere. Cells were free of
mycoplasma and were used from passage number 30 to
passage number 50.
Cytotoxicity assessment
Cells were seeded in suspension in 96-well microtitre plates
(SKOV-3, 5 x i03 cells per well; 41M, 7.5 x I03 cells per well)
and incubated for 24 h. Cisplatin and JM221 were added at
concentrations ranging from 0.01 to 200 ILM and 0.0025 to
100 fLM respectively for 2, 6, 24 or 96 h in quadruplicate for
each data point. On completion of the designated treatment
the drug-containing medium was discarded and cells were
washed sequentially in phosphate-buffered saline and medium
before the addition of drug-free medium and further incuba-
tion. The cytotoxicity of cisplatin and JM221 against these
cell lines assayed by [3H]thymidine has been previously
reported (Kelland et al., 1992). In these experiments, growth
inhibition was measured after 96 h by the sulphorhodamine
B assay, as follows. The medium was poured off, ice-cold
10% trichloroacetic acid was added and the cells were kept
on ice for 30 min. After washing five times with water, the
cells were stained with 100 ;l of 0.4% sulphorhodamine B in
1% acetic acid for 10-15 min, excess stain was washed off
with 1% acetic acid and the plates were air dried overnight.
The dye was solubilised with 100jil of 10 mM Tris and
absorption at 564 nm measured. The 50% inhibitory concen-
tration (IC50) was the drug concentration that reduced
absorption to 50% of that in untreated control wells.
Cellular platinum accumulation
Cisplatin and JM221 were added to exponentially growing cell
cultures (approximately 1 x 106 cells) in triplicate at concent-
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Figure 1 Chemical structures of cisplatin and JM221.
rations ranging from 2.5 to 100l4M for 2 h, and during
continuous 25gM drug exposure. On completion of the treat-
ment, the drug-containing medium was removed and the cells
were washed three times with ice-cold phosphate-buffered
saline. The cell monolayer was scraped, collected in 0.5 ml of
phosphate-buffered saline and sonicated (Soniprep 150,
Fisons, Loughborough, UK). Platinum concentrations of
sonicates were measured by flameless atomic absorption spec-
trophotometry (Perkin Elmer models 1IOOB and HGA700,
Ueberlingen, Germany), while the protein content was deter-
mined using the Lowry assay (Lowry et al., 1951). Cellular
platinum content was expressed as nmol of Pt per mg of
protein.
DNA platination
Cisplatin and JM221 were added to exponentially growing
cell cultures (approximately 5 x I07cells) at concentrations
ranging from 5 to 1I00 1M for 2 h. The drug-containing
medium was removed and replaced with drug-free medium.
For time-course studies, the cells were prelabelled with
['4C]thymidine in order to quantify DNA synthesis. At 0, 12
and 24 h following treatment, the cells were washed three
times with phosphate-buffered saline and harvested by tryp-
sinisation. DNA extraction was undertaken according to the
method of Kirby and Cook (1967). Briefly, cells were lysed
using a solution of 10mm Tris, 10mmEDTA, 0.15M
sodium chloride and 0.5% sodium dodecyl sulphate and
incubated at 60°C for 10 min, then overnight at 37°C. DNA
was extracted using a phenol solution (1 kg ofphenol, 150 ml
of m-cresol, 150 ml of water, 1 g of 8-hydroxyquinoline) and
ethanol precipitation. RNA was removed by the addition of
25 tlI 1% RNAase and incubation at 37°C for 1 h. DNA was
then re-extracted with phenol solution and ethanol precipita-
tion. Precipitates were air dried overnight and hydrolysed in
0.2% nitric acid. The platinum content of the hydrolysate
was determined by flameless atomic absorption spectro-
photometry and DNA concentration was measured using the
Burton (1956) assay. '4C counts of each DNA sample were
undertaken by scintilliation counting (Wallac 1410, Phar-
macia, Turku, Finland). Platination of DNA was expressed
as nmol of Pt per g of DNA and measurements in time-
course studies were corrected for ongoing DNA synthesis.
The correction factors for the final time-point ranged from 5
to 47%.
Alkaline elution
DNA interstrand cross-links were measured by alkaline elu-
tion as previously described (Kohn et al., 1981). Briefly,
6 x I05cells were seeded into 25-cm2 tissue culture flasks.
[I4C]thymidine was added after 24 h at 0.031iCi ml-' (specific
activity 51 mCi mmol-l, Amersham International, Amer-
sham, UK) to label DNA. Meanwhile, for the internal stan-
dard, 3.6 x 106cells were seeded in a 80-cm2 tissue culture
flask and labelled with [methyl-3H]thymidine at 0.17 ItCi ml1-
(specific activity 5 Cimmol-', Amersham) plus O0-5M
unlabelled thymidine. At 48 h test cells were exposed to
cisplatin and JM221 at concentrations ranging from 10 to
100gM for 2 h, after which cells were incubated in drug-free
medium. At 0, 12 and 24 h following treatment the cells were
washed three times with ice-cold phosphate-buffered saline
and harvested by trypsinisation. Duplicate samples of test
cells in phosphate-buffered saline (1 x I05 cells per 5 ml), and
a suspension of internal standard cells, were irradiated on ice
with 5 and 2 Gy respectively using 'Co '-rays from a 2000-
Ci source delivering 2 Gy min-'. Irradiated internal standard
cells (1 x I05cells) were added to the test cell suspensions
and kept on ice. The mixture was added to polycarbonate
filters (2#Am pore size, 2 cm diameter, Nucleopore Corpora-
tion, High Wycombe, Bucks, UK). Cells were lysed with two
sequential 5-ml additions of 2% sodium dodecyl sulphate,
0.1 M glycine and 0.1 M disodium EDTA (pH 10), the first
also containing proteinase K (0.5 mgml-'). The lysed cells
were washed with 5 ml of 0.05 M disodium EDTA. DNA wasCIRCUMVENTION OF RESISTANCE BY JM221 3
eluted at pH 12.2 using 10ml of 0.1 M tetrapropyl
ammonium hydroxide, 0.1% sodium dodecyl sulphate and
0.02 M EDTA at 0.01 ml min-'. Ten fractions were collected
at 90-min intervals over 15 h. '4C and 3H counts of each
fraction were made by liquid scintillation counting (Wallac
1410, Pharmacia) and expressed as fractions of 14C retained
vs fraction of 3H retained. The DNA cross-linking index was
calculated as follows:
Cross-linking index = ( [1 -r (control) } -l Cosd
1-r (test) )
where r is the fraction of '4C retention at 50% 3H retention
for control and test samples.
Statistics
The significance of differences was tested by unpaired or
paired t-tests. When a P value was less than 0.05 the
difference was regarded as significant.
Results
Cytotoxicity
The cytotoxicity of cisplatin and JM221 against the 41M and
SKOV-3 cell lines was studied following 2-96 h drug
exposure. The IC50 values are shown in Table I and represen-
tative growth inhibition curves are shown in Figure 2. The
41M line was ninefold more sensitive to cisplatin than the
SKOV-3 line at all exposure times, while their difference in
sensitivity to JM221 was only 2.7-fold. The dose potency of
JM221 was 5.2- to 29-fold greater than that of cisplatin in
the SKOV-3 line and 1.7- to 8.6-fold greater in the 41M line.
The cytotoxicity ofJM221 was highly time dependent since the
range of ICs values between 2 and 96 h drug exposure was
greater for JM221 (60-fold) than for cisplatin (12-fold).
Cellular platinum accumulation
Cellular platinum accumulation was studied in the SKOV-3
and 41M cell lines after cisplatin or JM221 treatment over a
range of doses immediately following 2 h exposure (Figure
3a) and over a time-course during continuous exposure to
25jAM (Figure 3b). Cellular platinum levels immediately fol-
lowing a 2 h exposure to JM221 were approximately 40-fold
higher in both the SKOV-3 (P<0.001) and 41M (P<0.001)
lines than immediately following an equimolar 2 h exposure
to cisplatin. Similarly, cellular platinum levels at time-points
ranging from 10 min to 24 h during continuous JM221
exposure were approximately 20-fold higher than cisplatin in
both the SKOV-3 (P<0.001) and 41M (P<0.001) lines.
Cellular platinum levels peaked at 15-24 h and accumulation
was most rapid during the first 2 h of treatment. The nine-
fold difference in cisplatin sensitivity between the SKOV-3
and 41M cell lines did not appear to be attributable to
transport mechanisms since there was no difference in cellular
platinum accumulation over a range of cisplatin concentra-
tions and time-points.
Table I Cytotoxicity (IC50, gm; mean+s.d., n = 3) of cisplatin and JM221 against the 41M and
SKOV-3 cell lines
Exposure time Cisplatin JM221
(h) 41M SKOV-3 Fold dff. 41M SKOV-3 Fold doff.
2 2.9± 1.2 26±4.5 8.9 1.7±0.3 4.9± 1.9 2.8
6 0.79±0.2 7.3±0.6 9.2 0.35±0.1 0.89±0.06 2.5
24 0.30±0.04 2.4±0.3 8.0 0.053±0.02 0.15±0.04 2.8
96 0.23± 0.08 2.1 ±0.15 9.0 0.028±0.016 0.073±0.02 2.6
IC50 ratio
(2 h/96 h) 12.6 12.2 67 62
aFold difference between cell lines.
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Figure 2 Representative growth inhibition curves of cisplatin and JM221 against the SKOV-3 and 41M cell lines following 2-96 h
drug exposure. (Drug exposure times: 2 h, open circles; 6 h, closed circles; 24 h, open triangles; 96 h, closed triangles).
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Figure 3 Cellular platinum content in the SKOV-3 and 41M cell
lines following cisplatin or JM221 exposure. a, Dose-response
immediately following 2 h exposures at concentrations ranging
from 2.5 to 100 !LM. b, Time-course during continuous 25ZlM
exposure (cisplatin, open symbols; JM221, closed symbols; 41M,
triangles; SKOV-3, circles; mean + s.d.; n = 3).
DNA platination
Levels of DNA-bound platinum were determined in the
SKOV-3 and 41M cell lines immediately following a 2 h
exposure to cisplatin or JM221 at concentrations ranging
from 5 to 100 tLM (Figure 4a), and at time-points ranging
from 0 to 48 h (Figure 4b). DNA-bound platinum
immediately following 2 h JM221 exposure was greater than
following cisplatin by a median of 4.1-fold (range 1.2- to
20-fold) in both the SKOV-3 (0.02>P>0.01) and 41M
(0.02>P>0.01) lines. DNA platination was not influenced
by ploidy since levels were similar in the diploid (41M) and
aneuploid (SKOV-3) cell lines. The ninefold difference in
cisplatin sensitivity of the 41M and SKOV-3 was not attri-
butable to a differences in DNA-bound platinum measured
immediately following 2 h cisplatin exposure.
DNA platinum levels following a 2 h exposure to cisplatin
fell by 60% by 48 h after treatment. By comparison, DNA
platinum levels were static from 0 to 48 h following a 2 h
exposure to JM221. The significant negative correlations seen
after cisplatin treatment between the logl0 of the percentage
change in DNA-bound platinum and time for both the
SKOV-3 (r = - 0.8013) and 41M (r = - 0.7900) lines were
consistent with monoexponential decay. The removal of
DNA-bound platinum following cisplatin treatment was
similar in the SKOV-3 and 41M cell lines and therefore did
not appear to account for their difference in cisplatin sen-
sitivity.
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Figure 4 DNA platination in the SKOV-3 and 41M cell lines
following cisplatin or JM221 exposure. a, Dose-response
immediately following 2 h exposure at concentrations ranging
from 5 to 100 iM (mean of two independent experiments). b,
time-course after a 2 h exposure (cisplatin 25giM; JM221 5jiM) at
time-points ranging from 0 to 48 h and linear regression analysis
of the logl0 of the DNA-bound platinum versus time (mean +
s.e.; n = 3-4) (cisplatin, open symbols; JM221, closed symbols;
41M, triangles; SKOV-3, circles).
analyses are shown in Tables II, III and IV, and a time-
course experiment is shown in Figure 6. JM221 caused inter-
strand cross-linking in a dose-dependent manner, however in
comparison with cisplatin there was less DNA interstrand
cross-linking with JM221. Immediately following a 2 h
equimolar exposure in the 41M line, cross-linking was three-
to sixfold more frequent with cisplatin than with JM221
(Figure 5 and Table III). Moreover, when cross-linking was
expressed as a function of the total DNA platinum lesions,
levels of DNA interstrand cross-linking induced by JM221
were 10-20% of those caused by cisplatin, in both cell lines
(Table IV). Also, after equitoxic 2 h exposures, the rate of
cross-link formation was slower and ultimate levels were
lower for JM221 than for cisplatin (Figure 6).
The comparison of cisplatin-induced DNA interstrand
cross-link formation in the cisplatin-sensitive (41M) and
-resistant (SKOV-3) cell lines (Table II, Figures 5 and 6),
over a range of both concentrations and time-points, showed
a 1.5- to twofold increase in cross-linking in the sensitive line.
Thus, DNA interstrand cross-linking was related to the int-
rinsic cisplatin sensitivity of these two human ovarian car-
cinoma cell lines. The difference in JM221-induced DNA
interstrand cross-linking in the two lines immediately follow-
ing 2 h exposure was attributable to a slower initial rate of
formation in the 41M line, since the levels of cross-linking
were similar at 12 and 24 h.
DNA interstrand cross-linking
DNA interstrand cross-linking was measured by alkaline elu-
tion after 2 h drug exposure at concentrations ranging from
25 to 100 jiM, and at time-points ranging from 0 to 24 h. A
representative experiment is shown in Figure 5, statistical
Discussion
The activity of cisplatin and JM221 were compared in a pair
of human ovarian carcinoma cell lines never previously
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Figure 5 Representative alkaline elution experiment in the SKOV-3 and 41M cell lines following 2 h exposure to cisplatin or
JM221 at concentrations ranging from 25 to 100tM (-, control; A, 25 juM; 0, 50 StM; *, 100 M).
Table II DNA interstrand cross-linking; comparison ofcell lines
Concentration Cross-linking index'
Treatment (AsM) SKOV-3 41M P
Cisplatin 25 0.064±0.01 0.11±0.024 <0.01
50 0.10±0.022 0.16±0.024 <0.05
100 0.14±0.048 0.29±0.082 <0.05
JM221 25 0.093±0.039 0.019±0.03 <0.05
50 0.10±0.039 0.062±0.03 NS
100 0.12±0.026 0.083±0.022 NS
aMean±s.d., n = 4. NS, not significant.
Table III DNA interstrand cross-linking; comparison ofdrugs
Concentration Cross-linking indexa
Cell line (OM) Cisplatin JM221 P
41M 25 0.11±0.024 0.019±0.03 <0.01
50 0.16±0.024 0.062±0.03 <0.01
100 0.29±0.041 0.084±0.022 <0.01
SKOV-3 25 0.064±0.01 0.093±0.039 NS
50 0.10±0.022 0.10±0.039 NS
100 0.14±0.048 0.12±0.026 NS
aMean±s.d., n = 4. NS, not significant.
Table IV Ratio of DNA interstrand cross-linking index and DNA
platination (x I0-3)a
Cisplatin JM221 P
41M 0.94±0.24 0.083±0.042 <0.01
SKOV-3 0.58±0.22 0.13±0.11 <0.05
aMean±s.d., n=3.
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Figure 6 Time-course of DNA interstrand cross-link formation
in the SKOV-3 and 41M cell lines following 2 h equitoxic
exposure to cisplatin (50gM) or JM221 (10gM) (mean ± s.e.;
n = 3-4; cisplatin, open symbols; JM221, closed symbols; 41M,
triangles; SKOV-3, circles).
exposed to platinum drugs, but displaying a ninefold
difference in cisplatin sensitivity. The cisplatin resistance was
therefore ascribable to intrinsic rather than acquired
mechanisms. JM221 reduced the cisplatin resistance factor
from nine- to 2.7-fold and was more dose potent than cis-
platin. Furthermore, JM221 displayed a marked time depen-
dency of cytotoxicity, with a decrease in IC50 of approxi-
mately 60-fold, compared with 12-fold for cisplatin, with an
increase in duration of drug exposure from 2 to 96 h. This
may be the result of comparatively slow reductive and
hydrolytic activation of this platinum (IV) complex and sug-
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gests that protracted administration schedules are of poten-
tial utility in vivo and clinically. Such administration
schedules may be clinically feasible with an oral prepara-
tion.
Cellular drug transport was measured by the determination
of total cellular elemental platinum content expressed as a
function of total cellular protein content. The platinum con-
tent ofcells exposed to JM221 was 20- to 40-fold higher than
that ofcells exposed to cisplatin, while the time-course profile
of platinum accumulation during continuous drug exposure
was similar for both drugs. Levels of platinum on DNA of
cells exposed to JM221 were also higher, by approximately
fourfold, than on DNA of cells exposed to cisplatin. These
results suggest that the activity of this lipophilic platinum
complex could be due to its improved transport properties,
however they also suggest that DNA binding may be more
efficient for cisplatin than for JM221 given equivalent intra-
cellular levels.
The removal of DNA-bound platinum was studied for 48 h
after 2 h exposure to JM221 or cisplatin by the determination
of total elemental platinum content on extracted DNA,
which would account for monofunctional, bifunctional, intra-
strand and interstrand lesions. In cells exposed to cisplatin
there was a gradual reduction in DNA platinum, not att-
ributable to ongoing DNA synthesis, by 60% at 48 h. By
comparison, cells exposed to JM221 showed no change in
levels of DNA-bound platinum over this time-course.
Nucleotide excision repair has been proposed as an impor-
tant mechanism of the repair and removal of platinum-
induced DNA damage (Parker et al., 1991; Dabholkar et al.,
1992). These results suggest that the activity of JM221 in
intrinsically resistant cancer might be due in part to the
circumvention of DNA repair mechanisms.
The DNA-drug interactions of this novel platinum com-
plex were further studied by alkaline elution. This bifunc-
tional lesion accounts for approximately 1% of total
DNA-bound platinum in cells exposed to cisplatin (Knox et
al., 1986), and it was, as a proportion of total DNA platinum
lesions, 10-20% less frequent with JM221 than with cis-
platin. Moreover, the absolute levels of JM221 DNA inter-
strand cross-linking were lower than cisplatin at equimolar
treatments in the 41M cell line, and the rate of JM221
cross-link formation was slower than that for cisplatin. These
results suggest that the reaction kinetics and spectrum of
DNA platinum adducts differ between JM221 and the con-
ventional platinum drug, and that lesions other than the
interstrand cross-link are critical for the antitumour action of
this novel octahedral platinum complex.
The SKOV-3 cell line was consistently ninefold less sensi-
tive to cisplatin than the 41M cell line over a range of
exposure times. Neither cellular platinum accumulation,
levels of DNA platination nor the rate of removal of
platinum from DNA related to this differential sensitivity.
Interstrand cross-linking, however, was consistently approxi-
mately twofold less frequent in the cisplatin-resistant SKOV-
3 line over a range of concentrations up to 100l1M and
time-points up to 24 h, and regardless of whether cross-
linking was expressed as absolute levels or as a proportion of
total DNA lesions. Intracellular glutathione levels have
previously been shown to be three times higher in the SKOV-
3 line than in the 41M line, although the activity of
glutathione S-transferases is similar in both cell lines (Mistry
et al., 1991). Furthermore, the SKOV-3 line was previously
exposed to thiotepa, a polyfunctional alkylating agent
capable of forming a variety of DNA adducts, including
interstrand cross-links, and for which covalent reaction with
cellular thiols such as glutathione is a potential resistance
mechanism (Colvin & Chabner, 1990). These results suggest
that the mechanism of intrinsic cisplatin resistance in the
SKOV-3 cell line is the inhibition of the formation of bifunc-
tional DNA adducts, possibly by the formation of gluta-
thione adducts, a feature that may relate to the history of
previous exposure to an alkylating agent.
In summary, intrinsic cisplatin resistance in a human
ovarian carcinoma in vitro model was attributable to the
inhibition of formation or bifunctional DNA lesions, while
the non-cross-resistant properties of JM221 were attributable
to both improved- transport properties and the circumvention
of DNA repair mechanisms.
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